

# The EUonQoL pilot study

OECI Oncology Days Athens

12 June 2025

**Sara Iadecola, MSc**

Unit of Biostatistics for Clinical Research

Fondazione IRCCS Istituto Nazionale Tumori - Milano



Fondazione IRCCS  
Istituto Nazionale dei Tumori

Sistema Socio Sanitario



Regione  
Lombardia

# Conflicts of interest disclosure

I do not have any actual or potential conflict of interest in relation to this presentation.

# Talk outline

- pilot study aims and design
- update on data collection
- sample description
- post-completion questionnaire results

# Study aims and design


---

# The EUonQoL pilot study: Aims

## Primary aim




- Assess **validity** and **reliability** of the EUonQoL-Kit (psychometric validation)



# The EUonQoL pilot study: Aims

## Secondary aims

- Assess EUonQoL-Kit **acceptability** and patient **burden**
- Cross-validate **static** and **dynamic** administration modes



# The EUonQoL pilot study: Design

Observational

Cross-sectional

Multicentre


Data collected at a  
single point in time

45 clinical centres from:

- 25 EU Member States
- 7 associated countries




- EU Member States
- Associated countries







# The EUonQoL pilot study: Design

Study population  
4,000 patients



4500 patients to account  
for missing data

EUonQoL-Kit static 	EUonQoL-Kit static FACT-G EQ-5D-5L 	EUonQoL-Kit static EUonQoL-Kit dynamic 	EUonQoL-Kit static EUonQoL-Kit static 
70%	10%	10%	10%
EUonQoL-Kit sample	Concurrent validity sample	Dynamic (CAT) sample	Test re-test sample



# The EUonQoL pilot study: Protocol paper

Apolone et al. *BMC Public Health* (2024) 24:3517  
<https://doi.org/10.1186/s12889-024-21008-4>

BMC Public Health

**STUDY PROTOCOL**

**Open Access**



## Validation of the European Oncology toolkit for the self-assessment of Quality of Life (EUonQoL-Kit) in cancer patients and survivors: study protocol of a pan European survey

G. Apolone<sup>1</sup>, M. Costantini<sup>1</sup>, L. Caselli<sup>1\*</sup>, N. Bos<sup>2</sup>, A. Caraceni<sup>3</sup>, G. Ciliberto<sup>4</sup>, N. Couespel<sup>5</sup>, M. Ferrer<sup>6,7,8</sup>, M. Groenvold<sup>9</sup>, S. Kaasa<sup>10</sup>, C. Lombardo<sup>11</sup>, R. Pietrobon<sup>12</sup>, G. Pravettoni<sup>13,14</sup>, A. Sirven<sup>15</sup>, H. Vachon<sup>16</sup>, G. Velikova<sup>17</sup>, O. Garin<sup>6,7,8</sup>, A. Gilbert<sup>17</sup>, A. Machiavelli<sup>12</sup>, C. Marzorati<sup>13,14</sup>, R. Miceli<sup>1</sup>, M. Pe<sup>16</sup>, MA. Petersen<sup>18</sup>, A. Tanzilli<sup>4</sup>, F. van Schelven<sup>2</sup>, C. Dantas<sup>19</sup>, I. Minnée-van Braak<sup>20</sup>, L. Pinnavaia<sup>21</sup> and C. Brunelli<sup>1</sup>

[euonqol.eu/results](https://euonqol.eu/results)



# Update on data collection

---

# The EUonQoL pilot study: Data collection

Data collection  
completed

43



Data collection  
ongoing

1




Data collection  
not started

1




# Patient accrual over time




**N = 4139**  
**on 24/03/2025**

# Sample size by validation sets



IN ACTIVE TREATMENT	1186	173	178	170
SURVIVORS	829	117	120	123
IN NEED OF PC	861	128	127	127

# Sample size by validation sets




IN ACTIVE TREATMENT	1186	173	178	170	1707 (41%)
SURVIVORS	829	117	120	123	1189 (29%)
IN NEED OF PC	861	128	127	127	1243 (30%)
TOTAL SAMPLE	2876 (70%)	418 (10%)	425 (10%)	420 (10%)	4139 (100%)

# Sample description


---

## Age at the date of registration







## Sex at birth




# Highest level of education



# Primary cancer diagnosis



# Eastern Cooperative Oncology Group (ECOG) Performance Status




## Post-completion questionnaire

---


# EUonQoL-Kit completeness

Participants with less than 3 items missing


In active treatment




Survivors



In need of PC




Total




# Post-completion results

**Difficulty in filling in  
the EUonQoL-Kit  
(patient-reported)**



# Post-completion results


Support needed to  
complete the  
EUonQoL-Kit






# Post-completion results

## Support needed for tablet use



## Support needed to interpret questions



# Conclusions

- **Target sample sizes** were met across validation and subpopulation groups
- The enrolled sample included **slightly more women**, with a **medium-high education level**, and an **age distribution consistent with an oncology population**
- There was **good variability in primary cancer types**, supporting generalizability of the results
- Clinical variables by the three subgroups aligned with expectations, with **patients in need of palliative care** showing worst clinical condition and **survivors** a better health status
- **Compliance data are encouraging:**
  - Over **95% of participants** completed the EUonQoL-Kit with fewer than 3 missing items
  - Most patients found the questionnaire **easy to complete**
  - **Limited external support to fill in the kit** was needed overall, including for tablet use and question interpretation

**Thank you for your attention**

**<https://www.euonqol.eu>**



This project received funding from the European Union  
Horizon Europe Research and Innovation Programme  
Grant Agreement N. 101096362